CY1119971T1 - Αναστολεις gsk-3 - Google Patents

Αναστολεις gsk-3

Info

Publication number
CY1119971T1
CY1119971T1 CY20181100217T CY181100217T CY1119971T1 CY 1119971 T1 CY1119971 T1 CY 1119971T1 CY 20181100217 T CY20181100217 T CY 20181100217T CY 181100217 T CY181100217 T CY 181100217T CY 1119971 T1 CY1119971 T1 CY 1119971T1
Authority
CY
Cyprus
Prior art keywords
gsk
suspensions
disease
alzheimer
insulin
Prior art date
Application number
CY20181100217T
Other languages
English (en)
Inventor
Ana MARTÍNEZ GIL
Miguel Medina Padilla
Mercedes Alonso Cascón
Ana Fuertes Huerta
María Luisa NAVARRO RICO
María José PÉREZ PUERTO
Ana Castro Morera
Ester MARTÍN APARICIO
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of CY1119971T1 publication Critical patent/CY1119971T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Η εφεύρεση σχετίζεται με παράγωγα ουρίας του χημικού τύπου (I) ως αναστολείς της κινάσης 3β συνθάσης γλυκογόνου, GSK-3, σε διαδικασίες παρασκευής τέτοιου είδους ενώσεων, σε φαρμακευτικές συνθέσεις που τις περιλαμβάνουν, και στη χρήση τους για τη θεραπεία και/ή την πρόληψη κάποιας νόσου στην οποία εμπλέκεται η GSK-3, όπως είναι για παράδειγμα η νόσος του Alzheimer ή ο μη-ινσουλινοεξαρτώμενος σακχαρώδης διαβήτης
CY20181100217T 2005-07-29 2018-02-22 Αναστολεις gsk-3 CY1119971T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380176A EP1749523A1 (en) 2005-07-29 2005-07-29 GSK-3 inhibitors
EP06776492.8A EP1919465B1 (en) 2005-07-29 2006-07-28 Gsk-3 inhibitors
PCT/EP2006/007520 WO2007017145A2 (en) 2005-07-29 2006-07-28 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
CY1119971T1 true CY1119971T1 (el) 2018-12-12

Family

ID=35445902

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100217T CY1119971T1 (el) 2005-07-29 2018-02-22 Αναστολεις gsk-3

Country Status (24)

Country Link
US (1) US8686042B2 (el)
EP (2) EP1749523A1 (el)
JP (1) JP5484726B2 (el)
KR (1) KR101471999B1 (el)
CN (1) CN101257900B (el)
AU (1) AU2006278829B2 (el)
BR (1) BRPI0615968B1 (el)
CA (1) CA2616451C (el)
CY (1) CY1119971T1 (el)
DK (1) DK1919465T3 (el)
ES (1) ES2661326T3 (el)
HK (1) HK1124761A1 (el)
HR (1) HRP20180109T1 (el)
HU (1) HUE036844T2 (el)
IL (1) IL189048A (el)
LT (1) LT1919465T (el)
NO (1) NO341454B1 (el)
NZ (1) NZ566380A (el)
PL (1) PL1919465T3 (el)
PT (1) PT1919465T (el)
RU (1) RU2449998C2 (el)
SI (1) SI1919465T1 (el)
WO (1) WO2007017145A2 (el)
ZA (1) ZA200800983B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2010008706A (es) * 2008-02-06 2010-08-30 Noscira Sa Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
CA2720659C (en) * 2008-04-24 2016-10-18 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)quinolin-4-yl)-3-(pyrazin-2-yl)urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
CN104940202B (zh) 2009-06-17 2018-10-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CA2810954A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2013173206A1 (en) * 2012-05-14 2013-11-21 University Of Kansas Phosphonate derivatives for treatment of alzheimer's disease
CN108865972B (zh) 2013-03-14 2022-07-29 布里格海姆妇女医院公司 一种细胞培养溶液
PL3068782T3 (pl) 2013-11-13 2018-12-31 Vertex Pharmaceuticals Incorporated Sposoby wytwarzania inhibitorów replikacji wirusów grypy
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
KR20230019500A (ko) 2014-09-03 2023-02-08 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CN106727556B (zh) * 2016-11-30 2017-10-20 鑫喆喆 一种治疗脑损伤的药物组合物
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895625A (en) * 1957-12-27 1962-05-02 Hoechst Ag New benzene-sulphonyl benzyl-ureas and process of preparing them
ES474449A1 (es) * 1978-10-23 1979-05-01 Invest Tecnica Aplicada Procedimiento de obtencion de ureas y tioureas con actividad farmacologica.
EP0131071B1 (en) * 1983-01-24 1987-05-13 Duphar International Research B.V Benzoylurea compounds, and pesticidal and pharmaceutical compositions comprising same
JPH10182588A (ja) * 1996-10-30 1998-07-07 Ss Pharmaceut Co Ltd 置換ベンジル尿素誘導体及びこれを含有する医薬
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
AU1296699A (en) * 1997-11-07 1999-05-31 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
AU2001245724A1 (en) * 2000-03-14 2001-09-24 Smith Kline Beecham Corporation Il-8 receptor antagonists
US6900041B2 (en) * 2000-10-02 2005-05-31 Reddy Us Therapeutics Inc. Methods and compositions for the treatment of inflammatory diseases
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
JP4613130B2 (ja) * 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
RU2008107733A (ru) 2009-09-10
EP1749523A1 (en) 2007-02-07
JP5484726B2 (ja) 2014-05-07
EP1919465B1 (en) 2017-12-27
US8686042B2 (en) 2014-04-01
CN101257900B (zh) 2012-09-12
EP1919465A2 (en) 2008-05-14
ZA200800983B (en) 2009-07-29
IL189048A0 (en) 2008-08-07
CA2616451C (en) 2015-01-20
IL189048A (en) 2017-04-30
NO341454B1 (no) 2017-11-13
CA2616451A1 (en) 2007-02-15
HUE036844T2 (hu) 2018-08-28
DK1919465T3 (en) 2018-02-05
SI1919465T1 (en) 2018-04-30
WO2007017145A2 (en) 2007-02-15
PL1919465T3 (pl) 2018-06-29
BRPI0615968A2 (pt) 2011-05-31
AU2006278829B2 (en) 2012-03-29
CN101257900A (zh) 2008-09-03
KR20080031440A (ko) 2008-04-08
NZ566380A (en) 2011-01-28
KR101471999B1 (ko) 2014-12-10
AU2006278829A1 (en) 2007-02-15
NO20081052L (no) 2008-02-28
WO2007017145A3 (en) 2007-04-26
LT1919465T (lt) 2018-04-10
BRPI0615968B1 (pt) 2023-10-03
JP2009502846A (ja) 2009-01-29
HK1124761A1 (en) 2009-07-24
RU2449998C2 (ru) 2012-05-10
PT1919465T (pt) 2018-03-07
US20090124686A1 (en) 2009-05-14
HRP20180109T1 (hr) 2018-04-20
ES2661326T3 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
CY1119971T1 (el) Αναστολεις gsk-3
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CY1118611T1 (el) Συνδυασμοι που περιεχουν παραγωγα της 6-βενζυλο-φαινυλο-2-θειοτετραϋδροπυραν-3,4,5-τριολης ως αναστολεις των συμμεταφορεων 1 και 2 νατριου-γλυκοζης για να χρησιμοποιηθουν σε διαβητικους ασθενεις
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1111507T1 (el) Ακυκλικοι αμινικοι αναστολεις των νουκλεοζιτικων φωσφορυλασων και υδρολασων
CY1108276T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
EA200801425A1 (ru) Диазепиноны
NO20075637L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater som medikamenter for behandling av infertilitet
ATE440836T1 (de) Verbindungen
CY1116032T1 (el) 8-χλωρο-3-πεντυλο-3,7-διυδρο-1η-πουρινο-2,6-διονο-2-αμινο-2-(υδροξυμεθυλο)-1,3-προπανοδιολη ανυδρο αλας για τη θεραπεια ασθενειων
NO20080104L (no) Inhibitorer av loselig adenylatsyklase
CY1117179T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
CY1117120T1 (el) Παραγωγα 1-ν-αζακυκλοαλκυλο-3-φαινοξυπροπανιου χρησιμα για την παρασκευη ψυχοτροπων φαρμακων
TH101434A (th) อนุพันธ์ 7-อัลไคนิล-1,8-แนพธิริโดน, การเตรียมสารนี้และการใช้สารนี้ในการรักษาโรค
TH128999A (th) อนุพันธ์ของ (เฮเทอโรไซเคิล/เททระไฮโดรพิริดีน)-(พิเพแรซินิล)-1-แอลคาโนน และอนุพันธ์ของ (เฮเทอโรไซเคิล/ไดไฮโดรพิร์โรลิดีน)-(พิเพแรซินิล)-1-แอลคาโนน ชนิดใหม่ และการใช้สารนั้นเป็นสารยับยั้ง p75
CY1114807T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για τη θεραπευτικη αντιμετωπιση ή την προληψη αυτοανοσων νοσων
CY1112061T1 (el) Παραγωγα πυριμιδινουριας ως αναστολεις κινασων
CY1116202T1 (el) Ενωσεις που περιεχουν διφθοριο ως αναστολεις των κυστεϊνικων πρωτεασεων